Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. - Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; et al. (The lancet. Gastroenterology & hepatology, 2023)